Breaking News: HSE weight-loss injections bill passed half a million euro a day last year

The rising cost of prescription weight-loss and diabetes injections is now a major issue in breaking news ireland, after new figures showed the HSE spent an average of more than €500,000 a day on the medicines last year. The latest data points to a sharp increase in the number of patients receiving Ozempic and Saxenda through State-backed drug schemes, highlighting a growing pressure point in ireland health news and wider public spending debates.

Records released under freedom of information show the HSE spent just under €212 million on Ozempic and Saxenda between January 2023 and September 2025. Around 80,000 patients received the drugs through free or subsidised schemes in 2025, with usage rising significantly compared with 2023.

How much the HSE spent on the injections

The figures indicate that Ozempic accounted for the biggest share of the total bill. The medicine is funded by the HSE for adults with diabetes under approved schemes, while Saxenda is available for weight management under specific reimbursement routes.

• Total spend on Ozempic and Saxenda from January 2023 to September 2025: nearly €212 million
• Average daily cost in 2025: about €550,000
• Patients receiving the drugs in 2025 through free schemes: roughly 80,000
• Increase in uptake since 2023: about one-third

That jump in demand makes this one of the more closely watched developments in ireland current affairs, especially as the health service balances medicine access with overall budget pressures.

What schemes were involved?

The spending was spread across the Long-Term Illness scheme, the medical card system and the Drugs Payment Scheme. The Long-Term Illness scheme covered the largest share of spending, with Ozempic prescribed to patients living with conditions such as diabetes. Unlike the medical card, this scheme is not means-tested.

Under the medical card route, both Ozempic and Saxenda were prescribed at a cost of more than €41 million during the period reviewed. A further €8.8 million was spent through the Drugs Payment Scheme.

Regional differences across the country

The newly released data also shows clear geographic variation, a detail likely to draw attention in ireland headlines and local coverage. Some HSE administrative areas recorded far higher numbers of patients receiving the injections than others.

For all free-drug schemes combined in 2025, Kildare and West Wicklow had the highest number of recipients, followed closely by North Dublin and Galway. At the other end of the scale, West Cork, Roscommon and Dun Laoghaire had the lowest totals.

• Kildare and West Wicklow: 4,531 patients
• North Dublin: 4,322 patients
• Galway: 3,991 patients
• West Cork: 1,007 patients
• Roscommon: 1,030 patients
• Dun Laoghaire: 1,148 patients

Looking specifically at the Long-Term Illness scheme, Kildare and West Wicklow also recorded the highest spend, at €9.7 million, with North Dublin and Galway again among the highest-use areas. For medical card patients, Galway and Limerick reported the largest numbers receiving the medicines in the first eight months of 2025.

Why Ozempic and Saxenda are being closely watched

Ozempic has become a high-profile medication internationally because of its association with weight loss, but the HSE position remains that it is reimbursed only for adults with insufficiently controlled diabetes. Saxenda, by contrast, is specifically funded for weight management in eligible cases.

This distinction matters in ireland health news because demand for GLP-1 medications has surged, both publicly and privately. These drugs work by helping to reduce appetite and improve blood sugar control, but their growing popularity also raises policy questions around access, cost and future reimbursement.

The HSE has said assessment processes are underway that will eventually determine whether newer treatments such as Mounjaro and Wegovy will be covered under State schemes. That means this is likely to remain a developing issue in ireland government news, ireland economy news and public healthcare planning.

Key questions readers are asking

Why is the spending so high?

Costs have risen because more patients are receiving the drugs and because these medicines are expensive over sustained periods of treatment.

Is Ozempic funded for weight loss by the HSE?

No. According to the HSE, Ozempic is funded for diabetes treatment, not for weight management. Saxenda is the medicine funded for weight loss in eligible cases.

Could more drugs be added to the schemes?

Yes, but only after formal review. The HSE has confirmed that reimbursement decisions on medicines such as Wegovy and Mounjaro are still being processed.

This story is more than a spending snapshot. It reflects how fast demand for GLP-1 medicines is changing healthcare budgets and treatment policy. As breaking news ireland continues to track costs, access and regional variation, the bigger question is whether the State can sustain rising demand while expanding treatment options fairly.